METHOD FOR INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH Russian patent published in 2006 - IPC A61K31/16 A61P35/00 

Abstract RU 2269339 C2

FIELD: organic chemistry, medicine, oncology, biochemistry, pharmacology.

SUBSTANCE: invention relates to the development of a method for inhibition in interaction of metalloproteinase 2 with integrin αvβ3 in host cells. Method involves contact of integrin with the amount of compound inhibiting this interaction and represented by the formula (I): wherein each of G1 and G2 represents independently -NH-C(O)-O-R1, -NH-C(O)-O-(CH2)v-(C6H4)-X3, -NH-C(O)-NH-(CH2)v-(C6H4)-X3, -O-C(O)-NH-(CH2)v-(C6H4)-X3, -O-C(O)-O-(CH2)v-(C6H4)-X3 or -NH-C(O)-CH2-(C6H4)-X3; each of Y1 and Y2 represents independently -OH, (C1-C4)-alkyl, (C1-C4)-hydroxyalkyl, (C1-C4)-alkoxy-group, phenyl, benzyl or -NH2; R1 represents (C1-C4)-alkyl; each of X1 and X2 represents independently halogen atom or (C1-C4)-alkoxy-group; X3 represents halogen atom, nitro-group, (C1-C4)-alkyl, (C1-C4)-alkoxy-group or (C1-C4)-perfluoroalkyl; Z represents -C≡C-, -C6H4-, cis-CH=CH-, trans-CH=CH-, cis-CH2-CH=CH-CH2-, trans-CH2-CH=CH-CH2-, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1,3-cyclohexyl, cis-1,4-cyclohexyl or trans-1,4-cyclohexyl; A represents hydrogen atom (H) or a covalent bond; each of m and n represents independently a whole number o or 1; t represents a whole number o or 1; each of p, r and v represents a whole number 1 or 2 and under condition that when A means hydrogen atom (H) then t is 0; when A means a covalent bond then t = 1, and when m = 0 then Y1 represents (C1-C4)-hydroxyalkyl, and when n = o then Y2 represents (C1-C4)-hydroxyalkyl. Also, invention describes a method for apoptosis induction involving administration of abovementioned substance in the therapeutically effective dose.

EFFECT: improved method for tumor inhibition, expanded assortment of antitumor agents.

37 cl, 9 dwg, 7 ex

Similar patents RU2269339C2

Title Year Author Number
COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITION OF TUMOR GROWTH (VARIANTS) 2001
  • Boger Dejl L.
  • Cheresh Dehvid A.
RU2276133C2
NUCLEIC ACID DELIVERY SYSTEM 2002
  • Cheresh Dehvid A.
  • Khud Dzhon
  • Bednarski Mark
RU2294192C2
PEPTIDE COMPOUNDS 2005
  • Katbertson Alan
  • Neharn Robert Dzhejms
RU2393167C2
ANTAGONISTS OF VITRONECTIN RECEPTOR, THEIR PREPARING AND APPLICATION 1997
  • Vener Fol'Kmar
  • Shtil'Ts Khans Ul'Rikh
  • Pejman Anushirvan
  • Knolle Jokhen
  • Rjukser Zhan-Mari
  • Karniato Deni
  • Lefransua Zhan-Mishel'
  • Gadek Tomas Richard
  • Mkdouehll Robert
RU2198892C2
COMBINED THERAPY BY USING PENTAFLUOROBENZENE SULFONAMIDES 2000
  • Shuendner S'Juzan
  • Timmermanz Piter
  • Uoling Dzheki
RU2268054C2
HETEROCYCLIC DERIVATIVES OF GLYCYL-BETA-ALANINE AS ANTAGONISTS OF VITRONECTIN 1999
  • Chandrakumar Nizal Sam'Juehl
  • Desaj Bipinchandra Nanubkhaj
  • Devadas Balekudru
  • Khaff Rene
  • Kkhanna Ish K.
  • Rao Shashidkhar N.
  • Riko Dzhozef G.
  • Rodzhers Tomas Eh.
  • Ruminski Piter G.
  • Rassell Mark Ehndr'Ju
  • Juj Ji
  • Gaziki Alan Frehnk
  • Malekha Dzhejmz U.
  • Mijashiro Dzhuli M.
RU2215746C2
INHIBITORS OF PROTEASES DECOMPOSING AFTER PROLINE 2002
  • Ivanz Dejvid Majkl
  • Ehshvort Dorin Mehri
RU2345065C2
PEPTIDE-BASED COMPOUNDS FOR DIRECTED TRANSPORT TO INTEGRIN RECEPTORS 2002
  • Katbertson Alan
  • Indrevoll Berd
  • Sol'Bakken Magne
  • Archer Kolin Mill
  • Ehngell Torgrim
  • Uodsvort Garri Dzhon
RU2303042C2
DIPHOSPHINE AND METAL COMPLEXES 2006
  • Kessel'Gruber Martin
  • Tommen Mark
  • Lotts Mattias
RU2408600C2
VERSIONS OF DISINTEGRIN AND THEIR PHARMACEUTICAL APPLICATION 2015
  • Chuan Voej-Tsze
RU2685869C1

RU 2 269 339 C2

Authors

Boger Dejl L.

Cheresh Dehvid A.

Dates

2006-02-10Published

2001-03-27Filed